By Makoto Ishii, MD, PhD
Assistant Professor of Neuroscience and Neurology, Feil Family Brain and Mind Research Institute, Department of Neurology, Weill Cornell Medical College
SYNOPSIS: In two national European biobanks, researchers identified and replicated 22 pairs of viral exposures associated with a higher risk of neurodegenerative diseases.
SOURCE: Levine KS, Leonard HL, Blauwendraat C, et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron 2023;111:1086-1093.e2.
Levine et al sought to systematically examine the potential associations between viral exposures and neurodegenerative disease risks in older adults using two large national biobanks.
FinnGen (Finnish biobank with genotyping data from more than 300,000 individuals) contained time series data and was used as a discovery phase cohort. The UK Biobank (genotyping data from nearly 500,000 individuals from the United Kingdom) with cross-sectional data was used as a replication phase cohort. The authors studied six neurodegenerative diseases: Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), generalized dementia, multiple sclerosis (MS), Parkinson’s disease (PD), and vascular dementia. They also examined 32 common viral illnesses, including influenza, viral encephalitis, meningitis, varicella-zoster virus, and viral warts.
Using ICD-10 codes, 45 significant neurodegenerative disease-virus associations were identified in FinnGen, with 22 of these replicated in the UK Biobank. All viral associations carried a higher risk of neurodegenerative diseases, with none associated with a protective effect. Most, but not all, viral associations (81%) were with viruses considered neurotropic.
Of the 22 associations that were found in both cohorts, the highest hazard ratio (HR) was seen between viral encephalitis and AD (discovery phase HR, 30.72; confidence interval [CI], 11.84-79.68; uncorrected P value, 1.89E-12; replication phase odds ratio [OR], 22.06; CI 5.47-88.94; uncorrected P value, 1.37E-05). In FinnGen, 24 of 406 viral encephalitis cases developed AD, which was significantly higher than the general prevalence of AD in this population (less than 3%).
The highest number of viral associations was in the generalized dementia category, with six (viral encephalitis, other viral diseases, viral warts, all influenza, influenza and pneumonia, and viral pneumonia) that were found in both FinnGen and the UK Biobank. Pneumonia caused by influenza was associated with five of the six neurodegenerative diseases (AD, ALS, generalized dementia, PD, and vascular dementia) in both FinnGen and the UK Biobank. As a positive control, the previously published finding of an association between a preceding Epstein-Barr virus exposure and higher MS risk was replicated in FinnGen but not in the UK Biobank, which may have been the result of differences in the use of diagnostic codes and the design of the two biobanks.
The authors then examined FinnGen to investigate if the viral infection could predate the neurodegenerative disease diagnosis. In general, the neurodegenerative disease risk was highest in the first year after a viral infection and decreased over time. Notably, some associations, such as generalized dementia and pneumonia caused by influenza, remained significant 15 years after the viral exposure.
Finally, to address the possibility of reverse causality or neurodegenerative diseases increasing the risk of acquiring viral infections, the authors examined the viral risk after a diagnosis of neurodegenerative disease. Although there was a moderate association between the risk of certain viral infections after a diagnosis of neurodegenerative disease, in general this was found to be significantly less than the risk of developing neurodegenerative disease after the viral exposure.
COMMENTARY
This important study provides further evidence linking several viral infections to the development of neurodegenerative diseases. Using longitudinal data in FinnGen, the strongest associations were in viral infections that preceded the neurodegenerative disease, which seemingly would suggest viral infections may be a causative agent. However, since many neurodegenerative diseases occur several years to decades before clinical diagnosis, it is possible that even those individuals with a viral exposure 15 years before neurodegenerative disease onset already were in the early stages of the neurodegenerative disease. Therefore, it would be important to examine viral exposures even earlier in life. Additionally, it is unknown if those with a viral exposure exhibited worse clinical severity of the neurodegenerative disease compared to those who never contracted the viral illness.
Finally, it is interesting to speculate the possible mechanisms linking viral infections and neurodegenerative diseases. One possibility is viral infections cause a general neuroinflammation. Another intriguing possibility is viral infections could trigger the core pathogenic factors of the neurodegenerative disease. Therefore, a viral infection could lead to more amyloid-beta production, which would help patients fight the viral infection but would be detrimental by exacerbating the burden of his or her AD pathology.
In two national European biobanks, researchers identified and replicated 22 pairs of viral exposures associated with a higher risk of neurodegenerative diseases.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content